#
HSV Cure Research 2026: New Vaccines, Antiviral Drugs and Clinical Trials
““Direct
Answer:”“ There is no cure for herpes simplex virus (HSV-1 or HSV-2) in 2026.
However, this year marked a genuine turning point: the FDA approved ““pritelivir
(Hovilpri)”“, the first antiviral with a new mechanism of action for HSV in
nearly three decades, specifically for immunocompromised adults with resistant
infections . Meanwhile, next-generation antivirals are advancing in trials, and
vaccine research continues—though no vaccine is close to approval.
##
The Approved Breakthrough: Pritelivir (Hovilpri)
On
October 9, 2026, the FDA approved pritelivir for adults with weakened immune
systems who have mucocutaneous HSV lesions that have not responded to
acyclovir, valacyclovir, or famciclovir, with or without documented resistance
. This includes patients with blood cancers, stem cell transplants, HIV, and
solid organ transplants.
###
Why It Matters
Standard
antivirals require activation by a viral enzyme called thymidine kinase. When
HSV mutates to lose that enzyme, those drugs fail. Pritelivir is a ““helicase-primase
inhibitor”“, meaning it blocks the viral DNA replication machinery directly,
without needing thymidine kinase . This makes it effective against resistant
strains.
###
The Phase 3 Data (PRIOH-1)
The
approval was based on a randomized trial of 101 immunocompromised adults . The
results were striking:
|
Outcome | Pritelivir | Older Treatments |
|
:--- | :--- | :--- |
|
““All lesions healed by Day 28”“ | ““63%”“ | 34% |
|
““All lesions healed by Day 42”“ | ““82%”“ | 42% |
|
““Discontinued due to side effects”“ | ““2%”“ | 20% |
The
most common side effect was headache, reported in 6% of pritelivir patients
versus 4% on comparators . Perhaps the most practical advantage: pritelivir is
a once-daily oral tablet taken at home, avoiding the daily IV infusions
(foscarnet or cidofovir) that were previously required for resistant cases .
##
Next-Generation Antivirals in Trials
““GS-1179
(Gilead Sciences):”“ A Phase 2b trial is comparing GS-1179 against valacyclovir
in HSV-2 seropositive adults with recurrent genital herpes. The study is
estimated to enroll 300 participants and is evaluating a ““once-weekly oral
dosing”“ regimen—a major shift from daily pills . This compound belongs to the
same helicase-primase inhibitor class as pritelivir.
““Adibelivir
(IM-250):”“ Preclinical data published in “Antiviral Research” in 2026 showed
adibelivir retained activity against acyclovir-resistant strains and
demonstrated synergistic effects when combined with acyclovir, penciclovir, or
foscarnet. Animal studies suggest it may affect the latent viral reservoir,
though this remains unproven in humans. Phase 2a trials are underway .
##
Vaccines: Modest Progress, Major Setbacks
There
is no approved HSV vaccine anywhere. The most advanced candidate is ““BioNTech's
BNT163”“, a preventive mRNA vaccine encoding HSV-2 glycoproteins gC2, gD2, and
gE2. It is currently in Phase 1 testing at six U.S. sites, with approximately
318 volunteers planned and the trial scheduled to run through October 2026.
Early results in 48 healthy adults showed mostly mild to moderate reactions and
a rise in antibodies, but ““no data yet on whether it prevents herpes”“ .
The
news is worse for therapeutic vaccines. ““Moderna's mRNA-1608”“, designed to
reduce outbreaks in people already infected with HSV-2, completed a Phase 1/2
trial of about 300 adults. The results, published in 2026, showed no major
safety concerns and increased binding and neutralizing antibodies, with
exploratory trends toward fewer recurrences . However, on November 20, 2025,
Moderna announced it would ““not move mRNA-1608 into Phase 3”“, citing broader
research budget cuts rather than safety or efficacy failure. No buyer or
partner has been announced .
##
The Cure Question: Gene Editing Remains Preclinical
For
patients hoping for a true cure—elimination of latent virus from nerve
cells—the most discussed approach is gene editing. The NIH's 2026 review is
candid about the barriers: delivery to sensory ganglia is inefficient,
off-target edits in neurons raise safety concerns, and animal models do not
faithfully reproduce human latency and reactivation . AAV-delivered
meganucleases and CRISPR-Cas9 have shown activity in animal models (mice and
rabbits), but neither has established safety or reached human trials for
genital or oral herpes . The review explicitly states these strategies
"must be regarded as strictly investigational" and should not be
misinterpreted as ready for clinical use.
##
What This Means for Patients
““If
you have a normal immune system and occasional outbreaks:”“ Standard antivirals
(acyclovir, valacyclovir, famciclovir) remain the first-line treatment.
Pritelivir is not approved for you.
““If
you are immunocompromised and standard drugs are failing:”“ Talk to your doctor
about pritelivir. It nearly doubled healing rates and offers an oral
alternative to IV therapy .
““If
you are waiting for a vaccine or cure:”“ Be cautious of anyone selling one. The
most credible near-term hope is better antivirals with more convenient dosing
(like GS-1179), not eradication of the virus. A vaccine is unlikely to be
available before approximately 2030, and even that estimate is uncertain .
##
Conclusion
2026
is a landmark year for HSV treatment—but not for a cure. Pritelivir's approval
fills a critical gap for immunocompromised patients with resistant infections,
and next-generation antivirals like GS-1179 are pushing toward more convenient
dosing. Vaccine research suffered a significant blow with Moderna's exit,
leaving BioNTech's early-stage program as the most advanced candidate. Gene
editing remains years from clinical reality. If you have herpes, the most
important step is to speak with a healthcare provider about which treatment is
appropriate for your specific situation.